Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-II receptor blockers (ARBs) are often administered to both diabetic and non-diabetic nephropathy patients, and are established as recommended treatment agents for non-diabetic nephropathy patients with albumin excretion [5]. This evidence concerns the gene ALB and diabetic kidney disease.